A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)
Open Access
- 23 July 2015
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 126 (4), 500-503
- https://doi.org/10.1182/blood-2015-03-631937
Abstract
Key Points Triple therapy is well tolerated and effective in patients with chronic ITP. Relapse free survival was 92% for responders after 12 months and 76% after 24 months.Keywords
This publication has 21 references indexed in Scilit:
- Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years durationHaematologica, 2014
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Early Stopping Rules in Clinical Trials Based on Sequential Monitoring of Serious Adverse EventsMedical Decision Making, 2008
- Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 studyBlood, 2008
- Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpuraHaematologica, 2008
- The Role of Autoreactive T-Cells in the Pathogenesis of Idiopathic Thrombocytopenic PurpuraInternational Journal of Hematology, 2005
- Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITPBlood, 2004
- Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An updateTransfusion Medicine Reviews, 2003
- Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpuraBlood, 2002
- Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomyBritish Journal of Haematology, 2001